NASDAQ:RXST RxSight (RXST) Stock Price, News & Analysis → Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad) Free RXST Stock Alerts $54.46 +2.12 (+4.05%) (As of 02:04 PM ET) Add Compare Share Share Today's Range$52.77▼$54.7350-Day Range$46.20▼$57.9252-Week Range$17.09▼$58.21Volume143,442 shsAverage Volume429,131 shsMarket Capitalization$2.01 billionP/E RatioN/ADividend YieldN/APrice Target$49.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get RxSight alerts: Email Address RxSight MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside8.9% Downside$49.63 Price TargetShort InterestHealthy4.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.85Based on 2 Articles This WeekInsider TradingSelling Shares$6.27 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.94) to ($0.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.64 out of 5 starsMedical Sector614th out of 910 stocksOphthalmic Goods Industry7th out of 7 stocks 1.5 Analyst's Opinion Consensus RatingRxSight has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRxSight has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.17% of the float of RxSight has been sold short.Short Interest Ratio / Days to CoverRxSight has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RxSight has recently decreased by 0.77%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRxSight does not currently pay a dividend.Dividend GrowthRxSight does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RXST. Previous Next 2.1 News and Social Media Coverage News SentimentRxSight has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for RxSight this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for RXST on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added RxSight to their MarketBeat watchlist in the last 30 days. This is a decrease of -78% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, RxSight insiders have sold 1,441.27% more of their company's stock than they have bought. Specifically, they have bought $406,680.00 in company stock and sold $6,268,022.00 in company stock.Percentage Held by Insiders21.13% of the stock of RxSight is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.78% of the stock of RxSight is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for RxSight are expected to grow in the coming year, from ($0.94) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RxSight is -38.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RxSight is -38.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRxSight has a P/B Ratio of 12.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is. About RxSight Stock (NASDAQ:RXST)RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.Read More RXST Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RXST Stock News HeadlinesApril 3, 2024 | insidertrades.comRxSight, Inc. (NASDAQ:RXST) CFO Shelley B. Thunen Sells 20,000 SharesApril 22, 2024 | globenewswire.comRxSight, Inc. to Report First Quarter Financial Results on May 6, 2024April 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 16, 2024 | americanbankingnews.comRxSight, Inc. (NASDAQ:RXST) Given Consensus Rating of "Buy" by AnalystsApril 13, 2024 | americanbankingnews.comNeedham & Company LLC Reiterates Buy Rating for RxSight (NASDAQ:RXST)April 11, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Abivax SA Sponsored ADR (ABVX), RxSight (RXST) and Clearside Biomedical (CLSD)April 11, 2024 | markets.businessinsider.comAssessing RxSight: Insights From 8 Financial AnalystsApril 6, 2024 | investing.comRxSight launches new Light Adjustable Lens productApril 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 4, 2024 | globenewswire.comRxSight Announces Commercial Launch of its Newest Light Adjustable Lens™, the LAL+™, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual MeetingMarch 27, 2024 | globenewswire.comRxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceMarch 14, 2024 | morningstar.comRxSight Inc RXSTMarch 4, 2024 | markets.businessinsider.comPatrick Wood Reaffirms Buy Rating for RxSight Amid Strong Growth and Market Expansion PotentialMarch 3, 2024 | ca.finance.yahoo.comRXST Mar 2024 70.000 callMarch 2, 2024 | finance.yahoo.comRxSight, Inc. (NASDAQ:RXST) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.75March 1, 2024 | finance.yahoo.comRxSight Full Year 2023 Earnings: EPS Beats ExpectationsFebruary 29, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on RxSight (RXST)February 29, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on RxSight (RXST)February 29, 2024 | globenewswire.comRxSight, Inc. to Participate in the 34th Annual Oppenheimer Healthcare ConferenceFebruary 29, 2024 | markets.businessinsider.comBuy Rating on RxSight: Strong Financials and Positive 2024 Outlook Drive Upward Price TargetFebruary 29, 2024 | finance.yahoo.comRxSight, Inc. (NASDAQ:RXST) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | markets.businessinsider.comForecasting The Future: 9 Analyst Projections For RxSightFebruary 28, 2024 | benzinga.comRecap: RxSight Q4 EarningsFebruary 28, 2024 | msn.comRxSight Non-GAAP EPS of -$0.13 beats by $0.14, revenue of $28.6M beats by $0.74MFebruary 28, 2024 | finance.yahoo.comRxSight Inc (RXST) Reports Significant Revenue Growth in Q4 and Full Year 2023February 28, 2024 | globenewswire.comRxSight, Inc. Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 24, 2024 | msn.comRxSight (RXST) Price Target Increased by 12.18% to 50.49See More Headlines Receive RXST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RxSight and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/23/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Ophthalmic goods Sub-IndustryN/A Current SymbolNASDAQ:RXST CUSIPN/A CIK1111485 Webwww.rxsight.com Phone949-521-7830FaxN/AEmployees374Year FoundedN/APrice Target and Rating Average Stock Price Target$49.63 High Stock Price Target$64.00 Low Stock Price Target$32.00 Potential Upside/Downside-5.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,610,000.00 Net Margins-54.57% Pretax Margin-54.55% Return on Equity-31.16% Return on Assets-25.51% Debt Debt-to-Equity RatioN/A Current Ratio8.06 Quick Ratio7.22 Sales & Book Value Annual Sales$89.08 million Price / Sales21.73 Cash FlowN/A Price / Cash FlowN/A Book Value$4.47 per share Price / Book11.71Miscellaneous Outstanding Shares36,990,000Free Float29,172,000Market Cap$1.94 billion OptionableOptionable Beta1.22 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Ronald M. Kurtz M.D. (Age 61)President, CEO & Director Comp: $1.03MMs. Shelley B. Thunen (Age 70)Chief Financial Officer Comp: $651.36kDr. Ilya Goldshleger Ph.D. (Age 49)Chief Operating Officer Comp: $657.81kMr. Eric J. Weinberg (Age 63)Chief Commercial Officer Comp: $638.9kMs. Rebecca WillistonVice President of Accounting & FinanceMr. Matt Haller Ph.D.Chief Technology OfficerAlex HuangInvestor RelationsMr. Roy FreemanVice President of MarketingMs. Caroline VaughnVice President of Human ResourcesMr. Scott GainesSenior VP of Commercial Operations & Business ProcessMore ExecutivesKey CompetitorsSTAAR SurgicalNASDAQ:STAANational VisionNASDAQ:EYEWarby ParkerNYSE:WRBYBausch Health CompaniesNYSE:BHCEdap TmsNASDAQ:EDAPView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCSold 1,617 shares on 4/18/2024Ownership: 0.506%Counterpoint Mutual Funds LLCBought 6,883 shares on 4/15/2024Ownership: 0.037%MCIA IncSold 4,100 shares on 4/11/2024Ownership: 0.022%Shelley B ThunenSold 20,000 sharesTotal: $998,000.00 ($49.90/share)Shelley B ThunenSold 10,000 sharesTotal: $563,700.00 ($56.37/share)View All Insider TransactionsView All Institutional Transactions RXST Stock Analysis - Frequently Asked Questions Should I buy or sell RxSight stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RxSight in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RXST shares. View RXST analyst ratings or view top-rated stocks. What is RxSight's stock price target for 2024? 6 Wall Street analysts have issued 1-year price objectives for RxSight's stock. Their RXST share price targets range from $32.00 to $64.00. On average, they expect the company's share price to reach $49.63 in the next year. This suggests that the stock has a possible downside of 8.9%. View analysts price targets for RXST or view top-rated stocks among Wall Street analysts. How have RXST shares performed in 2024? RxSight's stock was trading at $40.32 at the beginning of the year. Since then, RXST shares have increased by 35.1% and is now trading at $54.46. View the best growth stocks for 2024 here. When is RxSight's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our RXST earnings forecast. How were RxSight's earnings last quarter? RxSight, Inc. (NASDAQ:RXST) issued its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.36) by $0.10. The business earned $28.58 million during the quarter, compared to analyst estimates of $28.60 million. RxSight had a negative net margin of 54.57% and a negative trailing twelve-month return on equity of 31.16%. What ETFs hold RxSight's stock? ETFs with the largest weight of RxSight (NASDAQ:RXST) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Inspire Fidelis Multi Factor ETF (FDLS), Invesco DWA SmallCap Momentum ETF (DWAS), First Trust Small Cap Growth AlphaDEX Fund (FYC) and iShares Micro-Cap ETF (IWC).First Trust Small Cap Core AlphaDEX Fund (FYX). What guidance has RxSight issued on next quarter's earnings? RxSight issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $128.0 million-$135.0 million, compared to the consensus revenue estimate of $128.6 million. When did RxSight IPO? RxSight (RXST) raised $125 million in an initial public offering on Friday, July 30th 2021. The company issued 7,350,000 shares at $16.00-$18.00 per share. Who are RxSight's major shareholders? RxSight's stock is owned by a number of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.51%), Counterpoint Mutual Funds LLC (0.04%) and MCIA Inc (0.02%). Insiders that own company stock include Bakker Juliet Tammenoms, Eric Weinberg, Ilya Goldshleger, Jesse Anderson Corley, Robert Keith Warner, Ronald M Md Kurtz, Shelley B Thunen, Shweta Maniar and William J Phd Link. View institutional ownership trends. How do I buy shares of RxSight? Shares of RXST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RXST) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
